Monocyte matrix metalloproteinase production in Type 2 diabetes and controls - a cross sectional study

被引:32
作者
Baugh, Mark D. [1 ,2 ]
Gavrilovic, Jelena [2 ]
Davies, Isabel R. [1 ,3 ]
Hughes, David A. [3 ]
Sampson, Mike J. [1 ]
机构
[1] Norfolk & Norwich Univ Hosp NHS Trust, Bertram Diabet Res Unit, Norwich NR4 7UY, Norfolk, England
[2] Univ E Anglia, Sch Biol Sci, Norwich NR4 7UA, Norfolk, England
[3] AFRC, Inst Food Res, Norwich NR4 7UA, Norfolk, England
基金
英国生物技术与生命科学研究理事会;
关键词
D O I
10.1186/1475-2840-2-3
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Coronary plaque rupture may result from localised over expression of matrix metalloproteinases (MMPs) within the plaque by infiltrating monocyte - macrophages. As MMP expression can be promoted by the modified lipoproteins, oxidative stress and hyperglycaemia that characterises Type 2 diabetes, we hypothesised that peripheral monocytes in these patients, exposed to these factors in vivo, would demonstrate increased MMP production compared to controls. Methods: We examined peripheral venous monocyte expression of MMP and tissue inhibitor of metalloproteinase-1 (TIMP-1) in 18 controls and 22 subjects with Type 2 diabetes and no previous cardiovascular complications. Results: No significant difference in MMP-1, 3 or 9 or TIMP-1 production was observed between control and diabetes groups. Conclusions: Monocyte MMP-1, 3, and 9, and TIMP-1, production are not abnormal in Type 2 diabetes. This data cannot be extrapolated to monocyte - macrophage behaviour in the vessel wall, but it does suggest MMP and TIMP-1 expression prior to monocyte infiltration and transformation are not abnormal in Type 2 diabetes.
引用
收藏
页数:4
相关论文
共 23 条
[1]   Matrix metalloproteinase levels are elevated in inflammatory bowel disease [J].
Baugh, MD ;
Perry, MJ ;
Hollander, AP ;
Davies, DR ;
Cross, SS ;
Lobo, AJ ;
Taylor, CJ ;
Evans, GS .
GASTROENTEROLOGY, 1999, 117 (04) :814-822
[2]   HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages [J].
Bellosta, S ;
Via, D ;
Canavesi, M ;
Pfister, P ;
Fumagalli, R ;
Paoletti, R ;
Bernini, F .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1998, 18 (11) :1671-1678
[3]  
Borch-Johnsen K, 1999, LANCET, V354, P617
[4]  
Braschi S, 2001, DIABETOLOGIA, V44, pA321
[5]   MONOCLONAL-ANTIBODIES AGAINST HUMAN FIBROBLAST COLLAGENASE AND THE DESIGN OF AN ENZYME-LINKED-IMMUNOSORBENT-ASSAY TO MEASURE TOTAL COLLAGENASE [J].
CLARK, IM ;
POWELL, LK ;
WRIGHT, JK ;
CAWSTON, TE ;
HAZLEMAN, BL .
MATRIX, 1992, 12 (06) :475-480
[6]   Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-α production in NIDDM patients after gliclazide treatment [J].
Desfaits, AC ;
Serri, O ;
Renier, G .
DIABETES CARE, 1998, 21 (04) :487-493
[7]   Increased plasma metalloproteinase-9 concentrations precede development of microalbuminuria in non-insulin-dependent diabetes mellitus [J].
Ebihara, I ;
Nakamura, T ;
Shimada, N ;
Koide, H .
AMERICAN JOURNAL OF KIDNEY DISEASES, 1998, 32 (04) :544-550
[8]  
ENDEMANN G, 1993, J BIOL CHEM, V268, P11811
[9]   INCREASED EXPRESSION OF MATRIX METALLOPROTEINASES AND MATRIX-DEGRADING ACTIVITY IN VULNERABLE REGIONS OF HUMAN ATHEROSCLEROTIC PLAQUES [J].
GALIS, ZS ;
SUKHOVA, GK ;
LARK, MW ;
LIBBY, P .
JOURNAL OF CLINICAL INVESTIGATION, 1994, 94 (06) :2493-2503
[10]   Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteoglycan substrate for the enzyme [J].
Halpert, I ;
Sires, UI ;
Roby, JD ;
PotterPerigo, S ;
Wight, TN ;
Shapiro, SD ;
Welgus, HG ;
Wickline, SA ;
Parks, WC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (18) :9748-9753